Interestingly, a recent study demonstrated that EGFRvIII, due to its tumor-specific expression, can be successfully used in a SynNotch-CAR system, where it is responsible for turning on the expression of a dual-antigen–targeting CAR (IL13Rα2 and EphA2) at a tumor site. This evidence concerns the gene IL13RA2 and neoplasm.